Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide

W. T. Hughes, B. L. Smith, D. P. Jacobus

Research output: Contribution to journalArticle

Abstract

Pneumocystis carinii pneumonitis was prevented in 0, 50, 100, and 100% of immunosuppressed rats given doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day, respectively, of 4,4'-sulfonylbisformanilide (DFD). Therapeutic efficacy was demonstrated with DFD at 25.0 mg/kg per day, and when this dose was combined with trimethoprim, the combination was as effective as trimethoprim-sulfamethoxazole, which has been proven to be effective in the treatment of murine and human P. carinii pneumonitis.

Original languageEnglish (US)
Pages (from-to)509-510
Number of pages2
JournalAntimicrobial Agents and Chemotherapy
Volume29
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Pneumocystis carinii
Pneumonia
Trimethoprim
Sulfamethoxazole Drug Combination Trimethoprim
Body Weight
diformyl dapsone
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide. / Hughes, W. T.; Smith, B. L.; Jacobus, D. P.

In: Antimicrobial Agents and Chemotherapy, Vol. 29, No. 3, 1986, p. 509-510.

Research output: Contribution to journalArticle

@article{8a34ddabb706430a8c5b6f55e867670c,
title = "Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide",
abstract = "Pneumocystis carinii pneumonitis was prevented in 0, 50, 100, and 100{\%} of immunosuppressed rats given doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day, respectively, of 4,4'-sulfonylbisformanilide (DFD). Therapeutic efficacy was demonstrated with DFD at 25.0 mg/kg per day, and when this dose was combined with trimethoprim, the combination was as effective as trimethoprim-sulfamethoxazole, which has been proven to be effective in the treatment of murine and human P. carinii pneumonitis.",
author = "Hughes, {W. T.} and Smith, {B. L.} and Jacobus, {D. P.}",
year = "1986",
language = "English (US)",
volume = "29",
pages = "509--510",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide

AU - Hughes, W. T.

AU - Smith, B. L.

AU - Jacobus, D. P.

PY - 1986

Y1 - 1986

N2 - Pneumocystis carinii pneumonitis was prevented in 0, 50, 100, and 100% of immunosuppressed rats given doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day, respectively, of 4,4'-sulfonylbisformanilide (DFD). Therapeutic efficacy was demonstrated with DFD at 25.0 mg/kg per day, and when this dose was combined with trimethoprim, the combination was as effective as trimethoprim-sulfamethoxazole, which has been proven to be effective in the treatment of murine and human P. carinii pneumonitis.

AB - Pneumocystis carinii pneumonitis was prevented in 0, 50, 100, and 100% of immunosuppressed rats given doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day, respectively, of 4,4'-sulfonylbisformanilide (DFD). Therapeutic efficacy was demonstrated with DFD at 25.0 mg/kg per day, and when this dose was combined with trimethoprim, the combination was as effective as trimethoprim-sulfamethoxazole, which has been proven to be effective in the treatment of murine and human P. carinii pneumonitis.

UR - http://www.scopus.com/inward/record.url?scp=0022578140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022578140&partnerID=8YFLogxK

M3 - Article

C2 - 3487287

AN - SCOPUS:0022578140

VL - 29

SP - 509

EP - 510

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -